![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TGM3 |
Gene summary for TGM3 |
![]() |
Gene information | Species | Human | Gene symbol | TGM3 | Gene ID | 7053 |
Gene name | transglutaminase 3 | |
Gene Alias | TGE | |
Cytomap | 20p13 | |
Gene Type | protein-coding | GO ID | GO:0001942 | UniProtAcc | Q08188 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7053 | TGM3 | HCC1_Meng | Human | Liver | HCC | 2.05e-03 | 2.17e-02 | 0.0246 |
7053 | TGM3 | HCC1 | Human | Liver | HCC | 5.10e-04 | 2.31e+00 | 0.5336 |
7053 | TGM3 | HCC2 | Human | Liver | HCC | 1.60e-10 | 2.11e+00 | 0.5341 |
7053 | TGM3 | S027 | Human | Liver | HCC | 2.57e-02 | 2.80e-01 | 0.2446 |
7053 | TGM3 | S028 | Human | Liver | HCC | 5.42e-05 | 2.05e-01 | 0.2503 |
7053 | TGM3 | S029 | Human | Liver | HCC | 1.06e-17 | 4.90e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TGM3 | SNV | Missense_Mutation | c.1027N>G | p.Leu343Val | p.L343V | Q08188 | protein_coding | deleterious(0.02) | benign(0.07) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
TGM3 | SNV | Missense_Mutation | c.884N>A | p.Thr295Asn | p.T295N | Q08188 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A0J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
TGM3 | SNV | Missense_Mutation | c.1846C>T | p.Leu616Phe | p.L616F | Q08188 | protein_coding | tolerated(0.23) | benign(0.425) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
TGM3 | SNV | Missense_Mutation | rs150052126 | c.806G>A | p.Arg269Gln | p.R269Q | Q08188 | protein_coding | tolerated(0.21) | benign(0.053) | TCGA-EW-A2FR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | SD |
TGM3 | SNV | Missense_Mutation | novel | c.1929N>T | p.Lys643Asn | p.K643N | Q08188 | protein_coding | tolerated(0.07) | benign(0.236) | TCGA-LL-A8F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TGM3 | SNV | Missense_Mutation | novel | c.1798G>A | p.Glu600Lys | p.E600K | Q08188 | protein_coding | tolerated(1) | benign(0.014) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
TGM3 | SNV | Missense_Mutation | c.788N>T | p.Ser263Phe | p.S263F | Q08188 | protein_coding | deleterious(0.01) | probably_damaging(0.935) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
TGM3 | SNV | Missense_Mutation | c.1759G>A | p.Glu587Lys | p.E587K | Q08188 | protein_coding | deleterious(0.04) | benign(0.007) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
TGM3 | SNV | Missense_Mutation | rs150052126 | c.806G>A | p.Arg269Gln | p.R269Q | Q08188 | protein_coding | tolerated(0.21) | benign(0.053) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TGM3 | SNV | Missense_Mutation | rs774924175 | c.257N>T | p.Ala86Val | p.A86V | Q08188 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |